CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The purpose of this study is to evaluate if specific testing of vulva cancer tissue that is removed by surgery provides useful information to help decide if additional surgery is required or not.
The usual approach to treating early-stage vulvar cancer consists of a single surgery to remove the cancer.
The purpose of this study is to compare the effects on you and your endometrial cancer of a new drug in combination with radiation therapy compared to the current standard treatment of radiation therapy alone.
The purpose of this study is to identify people who may not require treatment after surgery or may require less treatment after surgery because their cancer is at such a low risk of coming back based on the specific tumour features found by the laboratory testing and the extent of tumour spread. Receiving no treatment or less treatment can result in no or fewer side effects (fatigue, hair loss, bowel and bladder irritation).
